Lorlatinib (lorlatinib) Drug Overview and Standardized Medication Guide

Lorlatinib (Lorlatinib, also known as lorlatinib) is a new third-generation tyrosine kinase inhibitor (TKI) developed by Pfizer Pharmaceuticals. This drug mainly targets anaplastic lymphoma kinase (ALK) and receptor tyrosine kinase c-ros proto-oncogene 1 (ROS1), marking another major development in the field of lung cancer treatment. Lorlatinib is uniquely designed to address the resistance problem of traditional ALK/ROS TKIs, providing new treatment hope for patients with advanced non-small cell lung cancer (NSCLC), especially those who are refractory to other ALK inhibitor treatments.

Lorlatinib, as a targeted therapy, is particularly effective and has excellent therapeutic effects on ALK-positive and ROS1-positive NSCLC patients. Clinical data show that lorlatinib has reached a high level of effectiveness in treating such patients, and it also shows good efficacy in patients with brain metastases, making it an important choice in the treatment of lung cancer.

In order to ensure the therapeutic effect of lorlatinib, patients should strictly follow the doctor's instructions and the medication instructions in the drug package insert. Generally, the recommended dose of lorlatinib is 100 mg orally once daily, with or without food. In order to maintain the stability of the drug effect, patients should try to take the drug at the same time every day. If you forget to take the medicine, you can take it again if it is not less than 4 hours before the next normal dose; otherwise, there is no need to take it again to avoid overdose.

During medication, patients should pay close attention to their body's reactions and possible adverse reactions. Common side effects of lorlatinib include swelling of the arms, legs, hands, and feet (edema), numbness and tingling in the joints or arms and legs (peripheral neuropathy), and difficulty thinking, breathing, and fatigue. If you encounter serious adverse reactions or decreased drug tolerance, you should report it to the doctor in time so that the doctor can adjust the medication plan according to the patient's specific situation.

In conclusion, lorlatinib is a highly effective drug for the treatment of lung cancer. Patients should fully understand its correct use and precautions, and use it rationally under the guidance of a doctor in order to obtain better treatment effects and quality of life. Currently, lorlatinib has both original and affordable generic versions to choose from. But no matter which version they choose, patients should ensure that they purchase it through formal channels to ensure the quality and safety of the medicine.